Predictors of medication adherence in patients with schizophrenia and bipolar disorder

Acta Psychiatrica Scandinavica

Volumn 127, Issue 1, 2012, Pages 23-33

  Jonsdottir H ^a,b   Opjordsmoen, S ^a,b   Birkenaes, A B ^a,b   Simonsen, C ^a   Engh, J A ^a,b   Ringen, P A ^a   Vaskinn, A ^a   Friis, S ^a,b   Sundet, K ^a,b   Andreassen, O A ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Adherence; Bipolar disorder; Predictors; Schizophrenia

Indexed keywords

AMPHETAMINE; CANNABIS;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; ATTENTION; BIPOLAR DISORDER; BLOOD ANALYSIS; BODY MASS; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATIONAL STUDY; EXECUTIVE FUNCTION; FEMALE; GENDER; HUMAN; INTELLIGENCE QUOTIENT; INTROSPECTION; LEARNING; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RISK ASSESSMENT; SCHIZOPHRENIA; SUBSTANCE ABUSE; WORKING MEMORY;

EID: 84871090339     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01911.x     Document Type: Article

References (82)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497.
2. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651.
3. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J, 425 VNSG. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-573.
4. Haynes RB, Mcdonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-2883.
5. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-175.
6. Gilmer TP, Dolder CR, Lacro JP et al.Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-699.
7. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.
8. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-172.
9. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J Clin Psychiatry 2005;66(Suppl 1):24-29.
10. Colom F, Vieta E, Tacchi MJ, Sánchez-Moreno J, Scott J. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005;7(Suppl 5):24-31.
11. Robinson DG, Woerner MG, Alvir JM et al.Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549.
12. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr 2007;12:21-26.
13. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286-290.
14. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002;159:1927-1929.
15. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.
16. Weiss KA, Smith TE, Hull JW, Piper AC, Huppert JD. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 2002;28:341-349.
17. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002;63:384-390.
18. Velligan DI, Lam YW, Glahn DC et al.Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006;32:724-742.
19. Awad AG. Antipsychotic medications: compliance and attitudes towards treatment. Curr Opin Psychiatry 2004;17:75-80.
20. Jónsdóttir H, Opjordsmoen S, Birkenaes AB et al.Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol 2010;30:169-175.
21. Krabbendam L, Arts B, Van Os J, Aleman A. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res 2005;80:137-149.
22. Simonsen C, Sundet K, Vaskinn A et al.Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull 2011;37:73-83.
23. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry 1996;153:321-330.
24. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:41-51.
25. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67(10):e12.
26. Vaskinn A, Sundet K, Simonsen C, Hellvin T, Melle I, Andreassen OA. Sex differences in neuropsychological performance and social functioning in schizophrenia and bipolar disorder. Neuropsychology 2011;25:499-510.
27. Martinez-Aran A, Vieta E, Torrent C et al.Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007;9:103-113.
28. Burdick KE, Goldberg JF, Harrow M. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up. Acta Psychiatr Scand 2010;122:499-506.
29. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-124.
30. Adams SG, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993;181:558-560.
31. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-797.
32. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 1996;169:444-450.
33. Smith TE, Hull JW, Goodman M et al.The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 1999;187:102-108.
34. Perkins DO, Gu H, Weiden PJ et al.Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-113.
35. Donohoe G, Owens N, O'donnell C et al.Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001;16:293-298.
36. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002;57:209-219.
37. Cuffel BJ, Alford J, Fischer EP, Owen RR. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis 1996;184:653-659.
38. Maeda K, Kasai K, Watanabe A, Henomatsu K, Rogers MA, Kato N. Effect of subjective reasoning and neurocognition on medication adherence for persons with schizophrenia. Psychiatr Serv 2006;57:1203-1205.
39. Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, Jeste DV. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res 2003;63:49-58.
40. Lepage M, Bodnar M, Joober R, Malla A. Is there an association between neurocognitive performance and medication adherence in first episode psychosis?Early Interv Psychiatry 2010;4:189-195.
41. Martinez-Aran A, Scott J, Colom F et al.Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry 2009;70:1017-1023.
42. Birkenaes AB, Søgaard AJ, Engh JA et al.Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. J Clin Psychiatry 2006;67:425-433.
43. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992;49:624-629.
44. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 2007;68:1540-1545.
45. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486.
46. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
47. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435.
48. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res 1995;14:229-234.
49. Bentsen H, Munkvold O-G, Notland T et al.The interrater reliability of the positive and negative syndrome scale (PANSS). Int J Meth Psych Res 1996;6:1-9.
50. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand 1994;89:62-67.
51. Jonsdottir H, Engh JA, Friis S et al.Measurement of insight in patients with bipolar disorder: are self-rated scales developed for patients with schizophrenia applicable?J Nerv Ment Dis 2008;196:333-335.
52. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
53. Ringen PA, Melle I, Birkenaes AB et al.Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr Scand 2008;117:133-138.
54. Sundet K, Vaskinn A. Estimating premorbid IQ (in Norwegian with English abstract). J Norwegian Psychological Association 2008;45:1108-1115.
55. Wechsler D. Wechsler Abbreviated Scale of Intelligence Scale (WASI). Norwegian manual. Stockholm: Pearson Assessment, 2007.
56. Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test - Second Edition (CVLT-II). Norwegian Manual supplement. Stockholm: Pearson Assessment, 2004.
57. Wechsler D. Wechsler Adult Intelligence Scale - Third Edition (WAIS-III). Norwegian manual. Stockholm: Pearson Assessment, 2003.
58. Haatveit BC, Sundet K, Hugdahl K, Ueland T, Melle I, Andreassen OA. The validity of d prime as a working memory index: results from the "Bergen n-back task". J Clin Exp Neuropsychol 2010;32:871-880.
59. Delis D, Kaplan E, Kramer J. Delis - Kaplan Executive Function System (D-KEFS). Norwegian Manual. Stockholm: Pearson Assessment, 2005.
60. Wechsler D. Wechsler Memory Scale - Third edition (WMS-III). Norwegian manual. Stockholm: Pearson Assessment, 2007.
61. Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 2007;21:129-141.
62. Yen CF, Chen CS, Ko CH et al.Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci 2005;59:403-409.
63. Peralta V, Cuesta MJ. Lack of insight in mood disorders. J Affect Disord 1998;49:55-58.
64. Clatworthy J, Bowskill R, Rank T, Parham R, Horne R. Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients' beliefs about the condition and its treatment. Bipolar Disord 2007;9:656-664.
65. Copeland LA, Zeber JE, Salloum IM, Pincus HA, Fine MJ, Kilbourne AM. Treatment adherence and illness insight in veterans with bipolar disorder. J Nerv Ment Dis 2008;196:16-21.
66. Jónsdóttir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand 2009;119:78-84.
67. Ringen PA, Lagerberg TV, Birkenaes AB et al.Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol Med 2008;38:1241-1249.
68. Mazzoncini R, Donoghue K, Hart J et al.Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand 2010;121:351-358.
69. Schubart CD, Boks MP, Breetvelt EJ et al.Association between cannabis and psychiatric hospitalization. Acta Psychiatr Scand 2011;123:368-375.
70. Miller R, Ream G, Mccormack J, Gunduz-Bruce H, Sevy S, Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 2009;113:138-144.
71. Van Rossum I, Boomsma M, Tenback D, Reed C, Van Os J, Board EA. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysisJ Nerv Ment Dis 2009;197:35-40.
72. Manwani SG, Szilagyi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry 2007;68:1172-1176.
73. Velligan DI, Weiden PJ, Sajatovic M et al.The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl 4):1-46.
74. Lieberman JA, Stroup TS, Mcevoy JP et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
75. Wittorf A, Sickinger S, Wiedemann G, Klingberg S. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Arch Clin Neuropsychol 2008;23:271-282.
76. Guo X, Zhai J, Wei Q et al.Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 2011;503:141-146.
77. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic reviewPsychol Med 2003;33:1149-1160.
78. Keck PE, Mcelroy SL, Strakowski SM et al.Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996;57:292-297.
79. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14:105-122.
80. Opjordsmoen S, Melle I, Friis S et al.Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early Interv Psychiatry 2009;3:58-65.
81. Mutsatsa SH, Joyce EM, Hutton SB et al.Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439-446.
82. Weiden PJ, Mackell JA, Mcdonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-57.